Sentence examples for additional cost effectiveness from inspiring English sources
The additional cost effectiveness was mainly derived from the lower total drug acquisition costs when fulvestrant is used as third-line hormonal therapy for advanced disease.
An additional cost effectiveness analysis will use the magnitude of a mean and median change on the Oswestry Disability Questionnaire as the natural unit of outcome.
Additional cost effectiveness ratios will be calculated as the total program cost per 10% change in functional independence (at discharge), and the total program and health service cost per 10% change in functional status between the control and intervention groups over a 12 month period.
In addition, an additional cost-effectiveness study would be useful to determine whether CHW interventions are a cost-effective alternative to health interventions to promote and prevent diseases.
The rationale for this procedure is that the QALY approach is seen critical by German authorities (especially by the IQWiG) and hence using clinical markers, to provide additional cost-effectiveness outcomes, will broaden the spectrum for argumentation.
Additional cost-effectiveness analyses, accounting for these studies, might be needed.
Additional cost-effectiveness analysis of PAD interventions is needed and should be included in all future peripheral vascular device trials.
Also the value of additional cost-effectiveness information for the model parameters is likely to be low.
As new, relevant evidence becomes available, additional cost-effectiveness evaluations should be undertaken to inform decision makers for current and future clinical practice in this important area.
Briefly, while the product was granted provisional reimbursement at a premium price at the time of initial manufacturer submission, additional cost-effectiveness analyses and follow-up studies enabled TLV to make a final positive reimbursement decision at the premium price.
11 Despite this, additional cost-effectiveness analyses based on TERISA data would be helpful in demonstrating ranolazine's cost-effectiveness in heavily β-blocker-treated population (as well as in a wider range of angina symptom frequencies and patients with diabetes).
